Peptide inhibitors of phosphoglycerate mutase and methods of use

US10808010B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• THE UNIVERSITY OF TOKYO · JP
• New England Biolabs, Inc. · US

Inventors

• James Inglese
• Patricia Dranchak · Gaithersburg, US
• Ryan MacArthur · Odenton, US
• Hiroaki Suga · Tokyo, JP
• Hao Yu · Hefei, CN
• Clotilde Carlow · Ipswich, US
• Zhiru Li · Lexington, US

Key dates

• Filing date: Aug 10, 2017
• Grant date: Oct 20, 2020
• Expiry date: Aug 10, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.